MarketLens

Is D3 Bio's Elisrasib a Game-Changer in KRAS G12C NSCLC

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Did D3 Bio Present at ASCO 2026 for Elisrasib

3 months ago

Is PetroChem Innovate's New Bio-Plastic a Game Changer for the Industry

4 months ago

What Makes Elisrasib's ASCO 2026 Data So Significant

3 months ago

What is Latus Bio's "Gene Therapy 2.0" and Why Does it Matter

4 months ago

MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology's Phase 3 THIO-104 trial for third-line advanced NSCLC reached 65 enrolled patients, with the latest assessment showing a 90.5% disease control rate in heavily pretreated patients.

MAIA

Stock News•1 week ago

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu

Akeso's HARMONi-2 study showed ivonescimab monotherapy delivered a statistically significant and clinically meaningful benefit versus pembrolizumab in PD-L1-positive advanced NSCLC, per partner Summit...

SMMT

Stock News•2 months ago

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Erasca's ERAS-0015 showed 57% uORR in 2L KRAS G12X pancreatic cancer at 32 mg QD RDE, with 100% median relative dose intensity. Company plans registration-enabling lung cancer trial in H1 2027 and Pha...

ERAS